Why in news?
A phase-1 trial using a single dose of a vaccine (Ad5-nCoV) that uses a recombinant adenovirus type-5 vector that carries the genetic material that codes for spike glycoprotein of novel coronavirus was found to be safe, well-tolerated and able to generate immune responses against the virus.
- The adenovirus is a weakened common cold virus.
- It was the first-in-human study of the adenovirus type-5 vectored COVID-19 vaccine.
- The vaccine was found to elicit neutralising antibodies, which peaked at day 28 post-vaccination, while rapid specific T-cell responses peaked at day 14 after vaccination.
- The antibody response to the vaccine in the high-dose group was slightly greater than that in the middle-dose and low-dose groups.
-Source: The Hindu